Replies to post #219471 on Biotech Values

[DewDiligence]

MRTX -17% on Sitravatinib mono/combo data at ESMO:

https://finance.yahoo.com/news/mirati-therapeutics-presents-updated-positive-101000005.html

https://finance.yahoo.com/news/mirati-therapeutics-announces-updated-data-091000385.html

The same theme pertains vis-à-vis addends to PD-(L)1 agents.